Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth

Masatomo Taniguchi, Masanori Tokumoto, Kazuhiko Tsuruya, Hideki Hirakata, Mitsuo Iida

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background. Both the phenotypic alterations of parathyroid (PT) cells, e.g. down-regulation of the calcium-sensing receptor, and the increase of the PT cell number in nodular hyperplasia are the main causes of refractory secondary hyperparathyroidism. It is of great importance to prevent PT growth in an early stage. Methods. To examine a more effective method of calcitriol therapy for the prevention of PT hyperplasia, we randomized haemodialysis patients with mild hyperparathyroidism to receive either daily orally administered calcitriol (n = 33) or intravenous calcitriol (n = 27) over a 12-month study period. Calcitriol was modulated so as to keep the serum intact PTH level between 100 and 150 pg/ml. Results. Both groups showed similar reductions of the serum PTH level and similar increases in serum calcium. In both groups, there were no significant changes in the serum phosphate level. Long-term daily oral calcitriol therapy failed to prevent the increase of both maximum PT volume and total volume, as assessed by ultrasonography; however, intravenous calcitriol therapy successfully suppressed this progression. In the daily, oral group, both the bone-specific alkaline phosphatase (BAP) and the N-telopeptide cross-linked of type I collagen (NTX) significantly decreased, which was probably due to the PTH suppression. However, these bone metabolism markers remained stable in the intravenous group. The total dosage of calcitriol during the study was comparable in both groups. Conclusions. These data indicate that intravenous calcitriol therapy in an early stage of secondary hyperparathyroidism is necessary to prevent PT growth and to keep a good condition of bone metabolism.

Original languageEnglish
Pages (from-to)3662-3669
Number of pages8
JournalNephrology Dialysis Transplantation
Volume23
Issue number11
DOIs
Publication statusPublished - Nov 1 2008

Fingerprint

Parathyroid Glands
Calcitriol
Growth
Secondary Hyperparathyroidism
Therapeutics
Serum
Bone and Bones
Hyperplasia
Calcium-Sensing Receptors
Hyperparathyroidism
Collagen Type I
Alkaline Phosphatase
Renal Dialysis
Ultrasonography
Down-Regulation
Cell Count
Phosphates
Calcium

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Transplantation

Cite this

Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. / Taniguchi, Masatomo; Tokumoto, Masanori; Tsuruya, Kazuhiko; Hirakata, Hideki; Iida, Mitsuo.

In: Nephrology Dialysis Transplantation, Vol. 23, No. 11, 01.11.2008, p. 3662-3669.

Research output: Contribution to journalArticle

Taniguchi, M, Tokumoto, M, Tsuruya, K, Hirakata, H & Iida, M 2008, 'Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth', Nephrology Dialysis Transplantation, vol. 23, no. 11, pp. 3662-3669. https://doi.org/10.1093/ndt/gfn264
Taniguchi, Masatomo ; Tokumoto, Masanori ; Tsuruya, Kazuhiko ; Hirakata, Hideki ; Iida, Mitsuo. / Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. In: Nephrology Dialysis Transplantation. 2008 ; Vol. 23, No. 11. pp. 3662-3669.
@article{599778ba14c44f77929694ca7255883c,
title = "Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth",
abstract = "Background. Both the phenotypic alterations of parathyroid (PT) cells, e.g. down-regulation of the calcium-sensing receptor, and the increase of the PT cell number in nodular hyperplasia are the main causes of refractory secondary hyperparathyroidism. It is of great importance to prevent PT growth in an early stage. Methods. To examine a more effective method of calcitriol therapy for the prevention of PT hyperplasia, we randomized haemodialysis patients with mild hyperparathyroidism to receive either daily orally administered calcitriol (n = 33) or intravenous calcitriol (n = 27) over a 12-month study period. Calcitriol was modulated so as to keep the serum intact PTH level between 100 and 150 pg/ml. Results. Both groups showed similar reductions of the serum PTH level and similar increases in serum calcium. In both groups, there were no significant changes in the serum phosphate level. Long-term daily oral calcitriol therapy failed to prevent the increase of both maximum PT volume and total volume, as assessed by ultrasonography; however, intravenous calcitriol therapy successfully suppressed this progression. In the daily, oral group, both the bone-specific alkaline phosphatase (BAP) and the N-telopeptide cross-linked of type I collagen (NTX) significantly decreased, which was probably due to the PTH suppression. However, these bone metabolism markers remained stable in the intravenous group. The total dosage of calcitriol during the study was comparable in both groups. Conclusions. These data indicate that intravenous calcitriol therapy in an early stage of secondary hyperparathyroidism is necessary to prevent PT growth and to keep a good condition of bone metabolism.",
author = "Masatomo Taniguchi and Masanori Tokumoto and Kazuhiko Tsuruya and Hideki Hirakata and Mitsuo Iida",
year = "2008",
month = "11",
day = "1",
doi = "10.1093/ndt/gfn264",
language = "English",
volume = "23",
pages = "3662--3669",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth

AU - Taniguchi, Masatomo

AU - Tokumoto, Masanori

AU - Tsuruya, Kazuhiko

AU - Hirakata, Hideki

AU - Iida, Mitsuo

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Background. Both the phenotypic alterations of parathyroid (PT) cells, e.g. down-regulation of the calcium-sensing receptor, and the increase of the PT cell number in nodular hyperplasia are the main causes of refractory secondary hyperparathyroidism. It is of great importance to prevent PT growth in an early stage. Methods. To examine a more effective method of calcitriol therapy for the prevention of PT hyperplasia, we randomized haemodialysis patients with mild hyperparathyroidism to receive either daily orally administered calcitriol (n = 33) or intravenous calcitriol (n = 27) over a 12-month study period. Calcitriol was modulated so as to keep the serum intact PTH level between 100 and 150 pg/ml. Results. Both groups showed similar reductions of the serum PTH level and similar increases in serum calcium. In both groups, there were no significant changes in the serum phosphate level. Long-term daily oral calcitriol therapy failed to prevent the increase of both maximum PT volume and total volume, as assessed by ultrasonography; however, intravenous calcitriol therapy successfully suppressed this progression. In the daily, oral group, both the bone-specific alkaline phosphatase (BAP) and the N-telopeptide cross-linked of type I collagen (NTX) significantly decreased, which was probably due to the PTH suppression. However, these bone metabolism markers remained stable in the intravenous group. The total dosage of calcitriol during the study was comparable in both groups. Conclusions. These data indicate that intravenous calcitriol therapy in an early stage of secondary hyperparathyroidism is necessary to prevent PT growth and to keep a good condition of bone metabolism.

AB - Background. Both the phenotypic alterations of parathyroid (PT) cells, e.g. down-regulation of the calcium-sensing receptor, and the increase of the PT cell number in nodular hyperplasia are the main causes of refractory secondary hyperparathyroidism. It is of great importance to prevent PT growth in an early stage. Methods. To examine a more effective method of calcitriol therapy for the prevention of PT hyperplasia, we randomized haemodialysis patients with mild hyperparathyroidism to receive either daily orally administered calcitriol (n = 33) or intravenous calcitriol (n = 27) over a 12-month study period. Calcitriol was modulated so as to keep the serum intact PTH level between 100 and 150 pg/ml. Results. Both groups showed similar reductions of the serum PTH level and similar increases in serum calcium. In both groups, there were no significant changes in the serum phosphate level. Long-term daily oral calcitriol therapy failed to prevent the increase of both maximum PT volume and total volume, as assessed by ultrasonography; however, intravenous calcitriol therapy successfully suppressed this progression. In the daily, oral group, both the bone-specific alkaline phosphatase (BAP) and the N-telopeptide cross-linked of type I collagen (NTX) significantly decreased, which was probably due to the PTH suppression. However, these bone metabolism markers remained stable in the intravenous group. The total dosage of calcitriol during the study was comparable in both groups. Conclusions. These data indicate that intravenous calcitriol therapy in an early stage of secondary hyperparathyroidism is necessary to prevent PT growth and to keep a good condition of bone metabolism.

UR - http://www.scopus.com/inward/record.url?scp=54149096979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54149096979&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfn264

DO - 10.1093/ndt/gfn264

M3 - Article

VL - 23

SP - 3662

EP - 3669

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 11

ER -